DR. MARYAM FOULADI, MD

Plain English
The study focused on a program called the Molecular Characterization Initiative, which aims to improve cancer treatment for children and young adults by providing them access to detailed genetic testing of their tumors. Since its launch in 2022, this initiative has enabled paired testing of tumor and genetic material, allowing doctors to receive important information that can guide treatment decisions. This matters because it helps standardize cancer care, leading to potentially better outcomes for young patients. Who this helps: This primarily helps pediatric cancer patients and their doctors.

Plain English
This study examined how two genes, myostatin (MSTN) and callipyge (CLPG), affect muscle growth in goat cells. Researchers used a gene-editing tool called CRISPR/Cas9 to alter these genes and found that when MSTN was knocked out, muscle-related genes increased significantly, with some showing up to a 30-fold rise in expression. This research is important because it paves the way for improving muscle growth in livestock, enhancing meat production efficiency. Who this helps: Farmers and livestock producers aiming to improve meat quality.

Plain English
This study looked at a new treatment approach for high-risk brain tumors in children by combining a drug that modifies DNA (decitabine) with an immune system booster (PD-1 inhibitor). Researchers found that while decitabine alone helped mice with some types of tumors (like certain diffuse intrinsic pontine gliomas and atypical teratoid rhabdoid tumors) live longer, combining it with the PD-1 inhibitor did not provide any additional survival benefit. This matters because it highlights the complexity of treating pediatric brain tumors and the need to explore alternative strategies for different tumor types. Who this helps: This research can help doctors identify the most effective treatments for children with specific types of brain tumors.

Plain English
This study looked at how to better classify and treat children with medulloblastoma, a type of brain cancer, by analyzing data from three clinical trials involving 898 patients. The researchers found that no single treatment was better than others in terms of survival, but adding a drug called carboplatin to a specific high-dose radiation treatment improved survival for some patients. They created a new risk classification system to help doctors identify which patients can safely receive less toxic treatment while still improving their chances of survival. Who this helps: This helps patients with medulloblastoma and their doctors by providing a clearer approach to treatment.

Plain English
This study looked at how brain tumors affect adolescents and young adults (aged 15-39) and the unique challenges they face in diagnosis and treatment. Researchers found that brain tumors are the second most common type of cancer in this age group, with malignant brain tumors being the leading cause of cancer-related deaths. To improve outcomes, the study emphasizes the importance of tailored care that combines new molecular testing and targeted therapies, highlighting the need for better collaboration between pediatric and adult healthcare systems. Who this helps: This helps young patients with brain tumors and their doctors.

Plain English
This research paper examines the importance of molecular testing for diagnosing and classifying brain tumors, which are part of the central nervous system (CNS). It found that without these tests, doctors may struggle to accurately identify and grade tumors, as the latest WHO guidelines now include specific molecular signatures for diagnosis. Additionally, these tests are cost-effective, making up less than 5% of total treatment costs, while greatly improving patient care through better diagnosis and treatment planning. Who this helps: This benefits patients with CNS tumors and their doctors.

Plain English
This study examined the effectiveness of a drug called selumetinib for children with recurring low-grade brain tumors, specifically looking at different patient groups. In total, 14 patients in one group showed a 7.1% response rate, while another group of 23 patients had a 21.7% response rate, both demonstrating some degree of stability in their disease. Overall, the findings indicate that selumetinib can help control tumor growth for a significant period, with some patients living more than two years without their disease worsening. Who this helps: This research benefits pediatric patients with low-grade gliomas, their families, and doctors managing their treatment options.

Plain English
This study looked at how to improve a new type of test called a liquid biopsy, which uses cerebrospinal fluid to monitor children with tumors in the brain and spinal cord. Researchers found a method that accurately detects tiny amounts of tumor DNA in the fluid, allowing them to catch signs of cancer recurrence earlier than traditional methods—one patient showed signs of returning cancer four months before any scans revealed it. This testing can help doctors manage treatment more effectively and intervene sooner when necessary. Who this helps: This helps children with brain and spinal tumors and their healthcare providers.

Plain English
This research focuses on high-grade gliomas, a type of brain tumor that primarily affects children and young adults. Scientists found that tumors with mutations in the IDH gene tend to have better outcomes and respond more favorably to treatment, though these mutations occur in about 5-15% of pediatric cases. Understanding these differences is important as it helps doctors tailor treatments for better results. Who this helps: This research benefits patients with high-grade gliomas, especially children and young adults.

Plain English
Researchers studied a combination treatment of a drug called veliparib, radiation, and chemotherapy (temozolomide) in children with high-grade glioma, a type of brain tumor. They found that among the 23 children treated, only 23% lived without disease progression after one year, while 64% survived overall. For a separate group of 14 children with a different tumor profile, 57% experienced no disease progression, and 93% were still alive after one year. These results matter because, although the treatment was safe and tolerable, it did not improve outcomes compared to previous treatments that used higher doses of chemotherapy. Who this helps: Patients with high-grade glioma and their families.

Plain English
This study looked at whether adding high doses of the drug methotrexate would help young children under 36 months old with high-risk embryonal brain tumors. Out of 59 children who received treatment, 28 (47.5%) experienced complete recovery, with those getting methotrexate showing better outcomes specifically in one type of tumor called Group 3 medulloblastoma (63% complete response) compared to those who did not receive it (30% complete response). This matters because finding effective treatments for these aggressive cancers can significantly improve survival rates in young children. Who this helps: This helps young children diagnosed with high-risk brain tumors and their families.

Plain English
This study examined whether adding chemotherapy to radiation therapy improves survival in children diagnosed with ependymoma, a type of brain tumor. The researchers followed 449 patients and found that five-year event-free survival was 69.2% for those who received both radiation and chemotherapy, compared to 63.7% for those who received radiation alone. Overall survival rates were also similar, with 88.3% for the combination treatment and 86.9% for radiation only, showing no significant benefit from chemotherapy after radiation. Who this helps: This research benefits doctors and families of children with ependymoma by providing clearer guidelines on the effectiveness of treatment options.

Plain English
This study focused on improving how doctors identify and analyze pediatric brain tumors, specifically a type called high-grade gliomas, which are rare and often deadly in children. The researchers organized a challenge called BraTS-PEDs 2023 to encourage the development of better computer programs (algorithms) that can automatically segment (break down) brain scans of these tumors. By using data from various international groups, they aim to enhance the accuracy and speed of tumor assessments, which can help increase the survival rates for affected children. Who this helps: This benefits children with brain tumors and their doctors.

Plain English
This study looked at how to improve treatments for pediatric brain tumors, which are the most common solid tumors in children and a leading cause of cancer deaths. Researchers found that current treatments are insufficient for high-grade tumors, highlighting the importance of using effective preclinical models to test new therapies. They are specifically exploring how to use immune checkpoint inhibitors (ICIs) alongside other treatments to better boost the immune response against these tumors. Who this helps: This research benefits children with high-grade brain tumors and their doctors by exploring more effective treatment options.

Plain English
This study focused on creating guidelines for early clinical trials (phase I and II) specifically for children, teens, and young adults with low-grade gliomas, which are a type of brain tumor. The researchers identified key issues like how to give the right dose of treatment, how long it should last, and how to measure if it works effectively. This is important because clear guidelines can help speed up the development of new treatments and ensure they improve the lives of young patients. Who this helps: This helps patients with low-grade gliomas, their families, and doctors involved in their treatment.

Plain English
In this study, researchers looked at the effects of two types of exercise—high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT)—on heart damage in diabetic rats, known as diabetic cardiomyopathy (DCM). They found that both types of exercise improved heart health by reducing inflammation and oxidative stress, leading to less cardiac damage. Specifically, exercise reduced harmful substances in the heart and improved overall function, showing that those who exercised had better outcomes than those who did not. Who this helps: This benefits patients with diabetes by highlighting the importance of regular exercise for heart health.

Plain English
This study looked at ways to improve survival for children with high-grade gliomas (HGG), a type of brain tumor. Researchers tested whether adding drugs vorinostat or bevacizumab to radiation treatment helped children survive without disease progression for at least a year, but they found that these combinations did not perform better than the standard drug temozolomide, with one-year event-free survival rates at about 44% for bevacizumab, 41% for vorinostat, and 59% for temozolomide. Importantly, children with certain tumor characteristics had much better outcomes: those without specific telomere maintenance mechanisms had a 100% event-free survival rate, indicating that understanding these tumor traits could lead to better treatment strategies in the future. Who this helps: This helps patients with high-grade gliomas and their doctors by providing insights into treatment options and tumor characteristics that influence survival.

Plain English
In this study, researchers looked at how different types of exercise, alone or combined with the diabetes drug metformin, can help prevent heart damage in diabetic rats. They found that both moderate exercise and high-intensity exercise, especially when combined with metformin, significantly improved heart function and reduced heart damage indicators. For example, the group that did high-intensity exercise with metformin showed the most improvement in heart health, suggesting that exercise is a powerful tool to protect against heart problems caused by diabetes. Who this helps: This benefits diabetic patients by offering strategies to protect their heart health.

Plain English
This research looked at how well the new drug ONC201 works for treating diffuse midline glioma (DMG), a difficult-to-treat brain tumor. The team found inconsistencies in the reports about how effective the drug is, which raises questions about its true benefits. Understanding these issues is important because it affects how doctors choose treatments for patients with DMG. Who this helps: This helps patients with diffuse midline glioma and their doctors.

Plain English
This study looked at the connection between Noonan syndrome, a genetic condition, and specific types of brain tumors called gliomas and glioneuronal tumors in young people. Out of 314 patients, 1.3% had a genetic variant linked to Noonan syndrome, and 60% of these individuals were diagnosed with the syndrome after their cancer diagnosis, which typically occurred at around age 17. This research is important because it shows how genetic testing can help identify patients at risk for these tumors, leading to better diagnosis and treatment options. Who this helps: This helps patients with Noonan syndrome and their doctors.

Plain English
This study looked at how different types of exercise and the diabetes medication metformin affect blood vessel damage in rats with diabetes. The researchers found that both interval and continuous exercise, along with metformin, significantly lowered blood sugar, cholesterol levels, and oxidative stress markers, improving overall blood vessel health. Specifically, combining interval training with metformin worked best, showing potential as an effective treatment for preventing heart-related issues in diabetic patients. Who this helps: This benefits diabetic patients looking to improve their heart health.

Plain English
This study looked at how two types of endurance exercise and the diabetes drug metformin affect memory problems caused by diabetes in rats. The researchers found that both high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT), along with metformin, helped improve memory and reduce harmful effects of diabetes, with significant improvements noted in various tests (p<0.01-p<0.001). These findings are important because they suggest that exercise and medication can work together to protect against memory loss related to diabetes. Who this helps: This helps patients with diabetes at risk of memory problems.

Plain English
This study focused on childhood brain tumors, which often have poor treatment outcomes despite advances in understanding the disease. Researchers from three international networks developed a set of guidelines to improve how new treatment ideas are evaluated before they are tested in patients. These guidelines help ensure that the studies are based on solid scientific evidence, making clinical trials more effective and targeted. Who this helps: This benefits patients with childhood brain tumors and the doctors treating them.

Plain English
This study looked at how well a drug called lenalidomide works for treating children with two types of brain tumors: pilocytic astrocytomas and optic pathway gliomas, after other treatments had failed. Researchers found that lenalidomide showed enough effectiveness, with four patients responding positively in each treatment group. Notably, children taking the lower dose of the drug had fewer side effects and tolerated the treatment better. Who this helps: This research benefits children with low-grade brain tumors and their doctors by providing a potentially safer treatment option.

Plain English
This study looked at young patients under 30 with a rare type of brain tumor called grade 4 gliomas, specifically comparing those who are kids to those who are young adults. Researchers found that on average, patients lived about 79 months after diagnosis and that younger patients (under 15) had worse survival rates than older ones, with only 7% experiencing serious side effects from treatment. This matters because understanding how age and tumor type affect survival can help doctors improve treatments for these patients. Who this helps: This helps patients with grade 4 gliomas and their doctors.

Plain English
This study focused on a new treatment called panobinostat for children with diffuse intrinsic pontine glioma (DIPG), a serious brain cancer with a survival time of less than one year. Researchers found that the highest safe dose of panobinostat was 10 mg/m² for those with worsening DIPG and 22 mg/m² for those with stable disease. The most common side effects were reductions in blood cell counts leading to anemia and infections, which is important to understand for managing patient care. Who this helps: This research benefits children with DIPG and their doctors by providing insights on how to safely use this medication.

Plain English
The Children's Oncology Group studied brain tumors in children, which are a major cause of illness and death in this age group. They found that, while new targeted therapies have been developed for these tumors, serious challenges still exist, especially for certain types like low-grade gliomas and high-grade gliomas that have poor outlooks. These findings are crucial because they highlight the need for better treatments and care strategies for affected children. Who this helps: This helps children with brain tumors and their families.

Plain English
This study looked at using a new type of material called boehmite nanoparticles to improve how we extract harmful chemicals known as chlorophenols from water. Using this material, researchers could detect 2,4-dichlorophenol at levels as low as 0.05 micrograms per liter and 2,4,6-trichlorophenol at just 0.003 micrograms per liter, showing that their method is both efficient and precise. This is important because it helps ensure cleaner water by effectively measuring pollutants that can harm health and the environment. Who this helps: This benefits environmental scientists and water quality testers.

Plain English
This study looked at how a drug called vorinostat works in combination with radiation therapy for children with a type of brain tumor called diffuse intrinsic pontine glioma (DIPG). Researchers tested the drug on 12 children during radiation and continued it for a while after; it was tolerated well with only 8.6% stopping due to side effects. However, the results showed that it did not significantly improve the chances of surviving or delaying disease progression, with only about 5.85% of children surviving without issues after one year. Who this helps: This information helps doctors and families make informed decisions about treatment options for children with DIPG.

Plain English
This study looked at the accuracy of brain scans in diagnosing diffuse intrinsic pontine glioma (DIPG) compared to actual tissue samples from patients. Out of 286 patients with tissue samples, 8% had a different diagnosis than DIPG, while 7% of the 569 patients with brain scans were suspected to have something other than DIPG. The findings show that central imaging reviews are very reliable: 99% of patients with classic DIPG imaging had corresponding DIPG diagnoses, and this imaging also helped predict survival outcomes. Who this helps: This benefits patients and doctors by improving DIPG diagnosis accuracy and potentially guiding treatment decisions.

Plain English
This study looked at how effective a simpler chemotherapy combined with lower radiation doses was for treating young patients, aged 3 to 21, with localized germinoma, a type of brain tumor. While the method aimed for a 3-year survival rate of at least 95%, the actual survival rates were still high at about 94.5% for those who received 18 Gy of radiation and 93.75% for those who got 24 Gy, though they did not meet the study's specific goal. The findings suggest this approach may lower long-term health issues while still effectively managing the cancer. Who this helps: This benefits young patients with localized germinoma and their families.

Plain English
This study looked at a new treatment approach for young children with severe brain tumors, specifically those under 4 years old. Researchers combined two medicines, vorinostat and isotretinoin, with standard chemotherapy, finding that 24 out of 31 patients finished the initial treatment in the expected time, and about 55% were still free of disease after five years. This is important because it shows that adding these two drugs is safe and might improve outcomes for children with tough-to-treat tumors. Who this helps: This benefits young patients with embryonal brain tumors and their families.

Plain English
In this study, researchers looked at how effective a lower dose of radiation therapy is for children with localized nongerminomatous germ cell tumors (NGGCT) after they responded to chemotherapy. They found that 87.9% of patients remained free of disease after four years, and 92.4% were still alive. However, they noted that relapse often happened in the spine, which indicates that the radiation treatment may need to be adjusted in future trials to better target this area. Who this helps: This study benefits children with NGGCT and their doctors by improving treatment plans and outcomes.

Plain English
This study focused on measuring tumor growth in patients with a type of brain tumor called DIPG, comparing traditional cross-sectional measurements to more detailed volumetric measurements. Researchers analyzed data from 46 patients and found that measuring tumor volume provided a clearer prediction of patient survival at various time points after treatment: a 30% increase in volume was linked to worsening survival odds, compared to the older method which didn't consistently predict survival as well. These findings highlight that using volumetric measurements can give better insights into how a patient's disease is progressing, potentially leading to improved patient management. Who this helps: Patients with DIPG and their doctors benefit from more accurate assessments of disease progression.

Plain English
This study looked at how a treatment called selumetinib affects children with a specific type of brain tumor known as low-grade glioma. The researchers found that certain imaging measurements, known as ADC histogram metrics, could predict how well the treatment works and how long the children might stay healthy after starting it. For example, children who responded to treatment showed greater reductions in their tumor measurements over time, suggesting they had better outcomes compared to those who didn't respond. Who this helps: This benefits children with low-grade gliomas and their healthcare providers by offering insights into effective treatments.

Plain English
This study looked at how well an anti-cancer drug called docetaxel sticks to tiny carbon structures known as graphene quantum dots, especially when modified with a specific polymer called PEG-b-PLA. The researchers found that while this polymer initially slows down how quickly the drug attaches, over time, it actually helps the drug dissolve better and stick more effectively, indicating a stable and useful method for drug delivery. These findings are important because they offer a potential way to improve cancer treatment by enhancing how well drugs reach their target in the body. Who this helps: This helps cancer patients by improving the delivery of treatments.

Plain English
This study focused on creating uniform guidelines for measuring how well treatments work for central nervous system (CNS) germ cell tumors, which affect children. The researchers found that current methods for assessing these tumors vary significantly between Europe and North America. By establishing new imaging standards, they aim to make it easier to compare treatment results from different regions, which is crucial for improving patient care. Who this helps: This helps patients with CNS germ cell tumors and their doctors.

Plain English
This study focused on young children, 3 years old and younger, diagnosed with a brain cancer called diffuse intrinsic pontine glioma (DIPG). Researchers found that among 40 eligible patients, the average survival time after diagnosis was 15 months, but 30% of the children survived longer than 2 years and one child lived over 5 years. This matters because it shows that with treatment, especially radiation, young children can have better outcomes compared to untreated ones. Who this helps: This helps doctors and families of young children diagnosed with DIPG by giving them hope and information about treatment options.

Plain English
This study assessed the combination of two drugs, ribociclib and everolimus, in children diagnosed with diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG) after they received radiation therapy. Out of 19 children enrolled, the recommended doses of the drugs were determined to be 170 mg/m² for ribociclib and 1.5 mg/m² for everolimus, and the results showed a median overall survival of 13.9 months for DIPG patients. Identifying effective treatments is crucial as these brain tumors are often aggressive and hard to treat. Who this helps: This research benefits children with DIPG and HGG by exploring new treatment options.

Plain English
This study looked at outcomes for children with pineoblastoma, a rare brain tumor, by combining data from North America and Australia. Researchers analyzed 178 cases and found that children under 3 years old have much lower survival rates: only about 14% are expected to survive without progression for 5 years, compared to about 61% for older children. This information is crucial for identifying at-risk groups and improving treatment strategies for these patients. Who this helps: This helps doctors and researchers understand risk factors to better treat young children with pineoblastoma.

Plain English
Researchers studied medulloblastoma, a type of brain cancer, and found that it isn't just one disease but consists of at least four different subtypes, each needing specific treatments. They highlighted that, even with these advancements, many patients still suffer from serious side effects and complications related to their tumors and treatments. By using modern strategies to better classify patients based on their specific medical and genetic characteristics, the aim is to tailor treatments—either reducing the intensity for those with lower risk or increasing it for those with higher risk to improve outcomes. Who this helps: This benefits patients with medulloblastoma and their doctors by guiding more tailored treatment options.

Plain English
This study looked at how likely children with brain tumors are to develop secondary cancers after receiving different types of radiation therapy: proton therapy and photon therapy. Researchers examined data from 24 studies and found that about 1.8% of children who received photon therapy and 1.5% who received proton therapy developed secondary cancers. It takes longer for children treated with photon therapy to develop secondary cancers, with an average of 11.9 years compared to just 5.9 years for those treated with protons. Who this helps: This information is valuable for doctors and families making treatment decisions for children with brain tumors.

Plain English
This study focused on improving how doxorubicin, a cancer drug, is delivered using specially modified gold nanoparticles. Researchers found that these nanoparticles effectively released up to 73.37% of the drug over 45 hours and showed little harm to healthy cells. This is important because it suggests a safer and more efficient way to deliver cancer treatment directly to tumors, potentially enhancing the therapy's effectiveness. Who this helps: Patients undergoing cancer treatment.

Plain English
This study looked at patients aged 10 years and older diagnosed with diffuse intrinsic pontine glioma (DIPG), a type of brain tumor. Out of 1,010 patients, 208 were over 10; their average survival after diagnosis was 13 months, with only 18 of them (about 11.8%) surviving longer than 2 years. The findings are important because they can help identify which older patients might have better outcomes, as those who survived longer tended to be older and had symptoms for a longer time before diagnosis. Who this helps: This helps patients and their families understand more about the characteristics and survival rates associated with DIPG in older children and young adults.

Plain English
This study looked at how different types of radiation therapy could affect children with average-risk medulloblastoma, a common brain cancer in kids. Researchers found that using a lower volume of radiation (involved field radiation therapy) was just as effective as a more targeted approach (posterior fossa radiation therapy), with similar five-year survival rates of around 82.5% and 80.5%. However, reducing the total radiation dose for younger children led to poorer outcomes, indicating the need for careful treatment planning based on individual biology to minimize side effects without sacrificing effectiveness. Who this helps: This benefits children with average-risk medulloblastoma and their families, as well as the doctors treating them.

Plain English
This study examined how a chemical known as perfluorocarbon (PFC) could help reduce dangerous inflammation and low oxygen levels in COVID-19 patients. Researchers found that PFCs might improve the body’s ability to manage a severe inflammation response (called a cytokine storm) by targeting a specific protein (HIF-1α) that contributes to this process. This is important because managing inflammation and oxygen levels effectively could improve outcomes for patients suffering from severe COVID-19 symptoms. Who this helps: This helps patients with severe COVID-19 and their doctors.

Plain English
This study examined the effectiveness of two drugs, carboplatin and isotretinoin, in treating children with high-risk medulloblastoma, a type of brain tumor. Researchers found that after 5 years, 66.4% of children treated with carboplatin were free of disease events, compared to 59.2% for those who did not receive it. Notably, the carboplatin treatment improved survival specifically in a subgroup of patients, showing a 73.2% event-free survival rate. Who this helps: This benefits children diagnosed with high-risk medulloblastoma and their doctors, by providing more effective treatment options.